Company recognized for innovations in clinically validated cell therapy for corneal endothelial dystrophies
Aurion Biotech Wins Clinical Advance of the Year Award at Biotech Week Boston
Recognition for its innovative cell therapy for corneal endothelial diseasesSeptember 19, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced it has received the Clinical Advance of the Year award from Biotech Week Boston.“Aurion Biotech is advancing a game-changing cell…
Aurion Biotech to Present Clinical Trial Results at the 2023 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
Efficacy data from Escalón study shows improvements in central corneal thickness and best corrected visual acuity May 2, 2023 – Seattle, Cambridge and Tokyo – Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced several presentations during the 2023 American Society of Cataract and Refractive Surgery (ASCRS)…
March Milestone
By Greg Kunst, CEO A lot of things seem to happen in March – Caesar’s assassination, Shakespeare’s Ides (a fortune-teller’s warning of the aforementioned assassination), the Spring Equinox, and (of course) March Madness.But Aurion’s most recent March Milestone augurs only good things – especially for the millions of patients around the world who suffer from…
Advanced Therapies for Ocular Diseases
We are a clinical-stage biotech company. We aim to restore vision to all who need it by developing a platform of innovative, accessible, and effective advanced therapies. Our first candidate is a patented cell therapy treatment for corneal endothelial disease.